S1212
Clinical - Urology
ESTRO 2026
Universitario 12 de Octubre, Terrassa, Spain. 16 Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, Malaga, Spain. 17 Department of Radiation Oncology, Hospital Clinico San Carlos, Madrid, Spain. 18 Department of Radiation Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. 19 Department of Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 20 Department of Radiation Oncology, Hospital Meixoeiro, Vigo, Spain. 21 Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. 22 Department of Radiation Oncology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. 23 Department of Radiation Oncology, Hospital Gómez Ulla, Madrid, Spain. 24 Department of Radiation Oncology, Hospital Rey Juan Carlos, Madrid, Spain Purpose/Objective: Trimodality therapy (TMT), combining maximal transurethral resection of the bladder tumor followed by concurrent chemoradiotherapy, has emerged as a bladder-preserving alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). Despite growing evidence, real-world multicenter data from European populations remain limited. Material/Methods:
2 RAIDER Randomised Controlled Trial. Eur Urol. 2025 Jan 1;87(1):60–70. 2. Chang YC, Wu YY, Tsan DL, Yap WK, Fan KH, Chang JTC, et al. Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection. Adv Radiat Oncol. 2024 Jan 12;9(1):101302. 3. Korpics MC, Block AM, Martin B, Hentz C, Gaynor ER, Henry E, et al. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. Cancer. 2017;123(18):3524– 31. Keywords: TMT, BCT, Dose escalation Prognostic Factors for Recurrence and Survival in Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer Nicolas Feltes Benitez 1 , Felipe Couñago 2,3 , Saturio Paredes-Rubio 1 , Paula Peleteiro Higuero 4 , Guadalupe Molina Osorio 5 , Alicia Folgar Torres 6 , Amina Aissati 7 , Arantxa Mera 8 , Jorge Pastor Peidró 9 , M. Isabel Garrido Botella 2 , María González de Dueñas 2,3 , Victor Duque- Santana 10,11 , Jose Torices Caballero 12 , Jon Andreescu Yagüe 13 , Aurora Rodríguez Pérez 14 , Sandra Fernández Alonso 15 , Antonio Lazo-Prados 16 , Miren Gaztañaga Boronat 17 , Sara Moreno Lopez 18 , Raquel García Gómez 19 , Patricia Willisch Santamaría 20 , Fernando López Campos 21 , Cecilia Nicolás Boluda 22 , Carmen Ibáñez Villoslada 23 , Elisabet González del Portillo 24 Poster Discussion 2078 1 Department of Radiation Oncology, Hospital Universitario de Terrassa (CST), Terrassa, Spain. 2 Department of Radiation Oncology, Hospital La Milagrosa, Madrid, Spain. 3 Department of Radiation Oncology, Hospital San Francisco de Asís, Madrid, Spain. 4 Department of Radiation Oncology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. 5 Department of Radiation Oncology, Institut Català d’Oncologia (ICO) Badalona, Barcelona, Spain. 6 Department of Radiation Oncology, Complexo Hospitalario Universitario de Lugo, Lugo, Spain. 7 Department of Radiation Oncology, Institut Català d’Oncologia (ICO) Girona, Girona, Spain. 8 Department of Radiation Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain. 9 Department of Radiation Oncology, ASCIRES Biomedical Group, Valencia, Spain. 10 Department of Radiation Oncology, Quirónsalud Madrid University Hospital, Madrid, Spain. 11 Departament of Medicine, Faculty of Medicine and Health Sciences, European University of Madrid,, Madrid, Spain. 12 Department of Radiation Oncology, Hospital Quirónsalud Barcelona, Barcelona, Spain. 13 Department of Radiation Oncology, GenesisCare Córdoba, Cordoba, Spain. 14 Department of Radiation Oncology, Hospital Ruber Internacional, Madrid, Spain. 15 Department of Radiation Oncology, Hospital
Between 2010 and 2022, a total of 669 patients with muscle-invasive bladder cancer were collected from multiple Spanish institutions participating in a national bladder-preservation registry. Of these, 369 node- negative, non-metastatic patients (cT2–T4aN0M0) received definitive trimodality therapy with curative intent and were included in this analysis, representing one of the largest European collaborative experiences to date.The primary endpoint was complete local response (CLR) after treatment; secondary endpoints included survival outcomes, recurrence patterns, and the need for salvage cystectomy. Logistic regression analyses were performed to identify prognostic factors associated with CLR Results:
Made with FlippingBook - Share PDF online